Comparison of ranibizumab and bevacizumab in neovascular age-related macular degeneration


Serdarogullari H., Ozturk M., Kayhan U., Bolukbasi S., Erden B., ELÇİOĞLU M. N.

International Eye Science, cilt.14, sa.5, ss.797-801, 2014 (Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 14 Sayı: 5
  • Basım Tarihi: 2014
  • Doi Numarası: 10.3980/j.issn.1672-5123.2014.05.03
  • Dergi Adı: International Eye Science
  • Derginin Tarandığı İndeksler: Scopus
  • Sayfa Sayıları: ss.797-801
  • Anahtar Kelimeler: Age-related macular degeneration, Anti-VEGF therapy, Bevacizumab, Choroidal neovascularization, Ranibizumab
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

AIM: To compare the efficacy of intravitreal ranibizumab and bevacizumab for the treatment of neovascular age-related macular degeneration (AMD) using a pro re nata (PRN) treatment regimen. METHODS: A total of 63 eyes (35 eyes treated with ranibizumab and 28 eyes treated with bevacizumab) of 63 patients with newly diagnosed neovascular AMD were analyzed and compared retrospectively. Outcomes included comparison of best-corrected visual acuity (BCVA) and central foveal thickness (CFT) after ranibizumab or bevacizumab treatment at 12 mo follow-up. Two-tailed t-tests and one-way ANOVA were used to compare mean changes in BCVA and CFT for different groups. RESULTS: Thirty-five eyes treated with ranibizumab and 28 eyes treated with bevacizumab were enrolled and completed 12mo follow-up. At 12 mo, mean BCVA increased by 0.1l ogMAR with ranibizumab treatment; however BCVA decreased by 0.06 logMAR with bevacizumab treatment (P=0.01). A gain of at least 0.3logMAR in BCVA was observed in 13 eyes (37%) treated with ranibizumab and in 4 eyes (14%) treated with bevacizumab. Mean CFT reduced by 41.6 μm and 8.1 μm in the ranibizumab and bevacizumab groups, respectively (P=0.003). The mean number of injections per eye was 4.46 with ranibizumab and 4.11 with bevacizumab (P>0.05). CONCLUSION: Intravitreal ranibizumab yielded better visual and anatomical results than bevacizumab. However, randomized long-term clinical trials are needed to draw conclusions about efficacy and safety of the two drugs.